Rituximab retention rate in systemic sclerosis: a long term real-life multicentre study.

ABSTRACT:

Objectives

To report real-life data on rituximab retention rate as an indicator of safety and efficacy in a multicentric national cohort of systemic sclerosis patients.

Methods

SSc patients treated with rituximab and followed for at least 36 months were included, clinically characterized and longitudinally monitored. A competing risk analysis with sub-hazard ratio (sHR) definition was performed to explore the clinical variables linked to specific cause of rituximab discontinuation.

Results

One-hundred and fifty-two SSc-patients [mean age 47.3 (12.3) years; females 79.6%; diffuse disease 77.6%; anti-topoisomerase-I positivity 63.2%] were evaluated over a median (interquartile range) time of 3.3 (1.7-5.0) years. The primary indications for rituximab were interstitial lu

SUBMITTER: De Luca G 

PROVIDER: S-EPMC11879284 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature